- PD-1 is a checkpoint protein on immune cells called T cells
- Normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body
- Does this when it attaches to PD-L1, a protein on some normal (and cancer) cells
- When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone
- Some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack.
PDL1 ADC for PDL1 Positive Tumors
Partnering Immuno-Oncology
Life Saving Cancer Treatments!
Extensive Inventory of Proprietary Co-stimulatory Agents and Checkpoint Inhibitors
= Multiple Revenue Opportunities
PD-L1 Inhibitors
Revolutionized Immuno-Oncology
Molecular Templates (“MTEM”)
Engineered Toxin Bodies (ETBs) with Lanier’s Proprietary PD-L1 Inhibitor
- ETBs platform represents a new class of targeted therapy with unique biological properties
- ETBs work through a unique intracellular mechanism of action: enzymatic and permanent ribosome inactivation
- A Phase 1 study in relapsed/refractory patients with PD-L1 expressing tumors paid out initial milestone
PD-L1 Checkpoint Inhibitor is Involved in Many Tumor Types
